Login / Signup

Patient-centered dosing: oncologists' perspectives about treatment-related side effects and individualized dosing for patients with metastatic breast cancer (MBC).

Anne L LoeserLucy GaoAditya BardiaMark E BurkardKevin M KalinskyJeffrey PeppercornHope S RugoMartha CarlsonJanice CowdenLesley GlennJulia MauesSheila McGlownAndy NiNatalia PadronMaryam Lustberg
Published in: Breast cancer research and treatment (2022)
Treatment-related side effects are prevalent among patients with MBC, resulting in missed treatments and acute care visits. To help patients tolerate treatment, oncologists may decrease initial and/or subsequent doses. The majority of oncologists reject the premise that a higher dose is always superior and are willing to discuss individualized dosing with patients. Given potential improvements regarding quality of life and clinical care, dose modifications should be part of routine shared decision-making between patients and oncologists.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • peritoneal dialysis
  • metastatic breast cancer
  • quality improvement